scholarly journals Preliminary Results of “Bonadiuv” Trial: A Single-Blind, Randomized, Placebo-Controlled Study Designed to Evaluate the Impact of Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Taking Aromatase Inhibitors

2013 ◽  
Vol 24 ◽  
pp. iii16 ◽  
Author(s):  
S. Cecchini ◽  
V. Scotti ◽  
I. Meattini ◽  
M.L. De Feo ◽  
C. De Luca ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Controlled Study ◽  
Bisphosphonate Treatment ◽  
Mineral Density ◽  
Preliminary Results ◽  
The Impact ◽  
Single Blind

Genetic determinants of bone mineral density loss in aromatase inhibitors treatment in the B-ABLE Cohort

2014 ◽  
Author(s):  
Maria Rodriguez-Sanz ◽  
Natalia Garcia-Giralt ◽  
Pliego Elisa Torres-del ◽  
Daniel Prieto-Alhambra ◽  
Sonia Servitja ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Genetic Determinants ◽  
Mineral Density ◽  
Bone Mineral Density Loss

scholarly journals A REVIEW: MECHANISTIC INSIGHTS INTO THE EFFECT OF THYROID DISORDERS ON ESTROGEN LEVEL AND BONE MINERAL DENSITY

2019 ◽  
pp. 9-17
Author(s):  
MINAKSHI JOSHI ◽  
SHRADHA BISHT ◽  
MAMTA F. SINGH
Keyword(s):  
Bone Mineral Density ◽  
Thyroid Hormone ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Disorders ◽  
Hypothyroid Patient ◽  
Mineral Density ◽  
Estrogen Level ◽  
The Impact

Thyroid hormone serves as an indispensable component for the optimum functioning of various biological systems. They curb body’s metabolism, regulates the estrogen level, regulates bone turnover, essential for skeletal development and mineralization. Within the scope of knowledge, it is intimately familiar that thyroid disorders have widespread systemic manifestations, among which in hypothyroidism, even though elevated TSH (thyroid-stimulating hormone) may reduce estrogen level which in turn stimulates osteoclasts and thus cause osteoporosis, while hyperthyroidism accelerates bone turnover. Hypothyroidism does not directly interfere with the skeletal integrity, but treatment with levothyroxine for the suppression of TSH to bring the hypothyroid patient to euthyroid state for a long haul; lead to simultaneous reduction in bone mass and in (bone mineral density) BMD. After the initial relevation of the correlation between thyroid disorders and osteoporosis in numerous studies have emphasized that both hypo and hyperthyroidism either directly or indirectly affects the bone mineral density or leads to the progression of osteoporosis. Therefore the present study is aimed and so designed to review all the possible associations between them and the impact of thyroid disorders on estrogen level and bone mineral density. The main findings of this review indicate that both excesses as well as deficiency of thyroid hormone can be potentially deleterious for bone tissue.

scholarly journals Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stefana Catalina Bilha ◽  
Letitia Leustean ◽  
Cristina Preda ◽  
Dumitru D. Branisteanu ◽  
Laura Mihalache ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Mineral Density ◽  
Cross Sectional ◽  
The Impact

Abstract Background Despite the increased fracture risk, bone mineral density (BMD) is variable in type 1 (T1D) and type 2 (T2D) diabetes mellitus. We aimed at comparing independent BMD predictors in T1D, T2D and control subjects, respectively. Methods Cross-sectional case-control study enrolling 30 T1D, 39 T2D and 69 age, sex and body mass index (BMI) – matched controls that underwent clinical examination, dual-energy X-ray absorptiometry (BMD at the lumbar spine and femoral neck) and serum determination of HbA1c and parameters of calcium and phosphate metabolism. Results T2D patients had similar BMD compared to T1D individuals (after adjusting for age, BMI and disease duration) and to matched controls, respectively. In multiple regression analysis, diabetes duration – but not HbA1c- negatively predicted femoral neck BMD in T1D (β= -0.39, p = 0.014), while BMI was a positive predictor for lumbar spine (β = 0.46, p = 0.006) and femoral neck BMD (β = 0.44, p = 0.007) in T2D, besides gender influence. Age negatively predicted BMD in controls, but not in patients with diabetes. Conclusions Long-standing diabetes and female gender particularly increase the risk for low bone mass in T1D. An increased body weight partially hinders BMD loss in T2D. The impact of age appears to be surpassed by that of other bone regulating factors in both T1D and T2D patients.

Sign in / Sign up

Export Citation Format

Share Document